Accelerator 

The RNA Accelerator is the core facility within the UNSW RNA Institute and the NSW RNA Production Research Network (NSW-RPRN).

 

It is the Institute’s nucleus, designed to expedite the discovery, manufacture and translation of RNA-based therapeutics and other products. 

The Accelerator supplies high-quality RNA and nanoparticle formulations under ISO-9001 conditions for pre-clinical studies.

The UNSW RNA Accelerator facility consist of four main units for the production of:

 

  • mRNA (by in vitro enzymatic transcription)  

  • synthetic RNA (including siRNA, aptamers and guide RNA)  

  • DNA plasmids (a precursor for mRNA production)  

  • a lipid nanoparticle formulation suite.   

Each of these units have scale-up capabilities and are equipped with state-of-the-art instruments for the production/synthesis, purification and quality control (analysis) of all materials.

The facility is ISO 9001 Certified for the ‘Pilot-scale manufacture and design and development of new processes for RNA-based therapeutics and other products for pre-clinical studies.'

Production capabilities

The manufacturing arm of the UNSW RNA Institute, the RNA Accelerator, gives clients access to RNA-based therapeutics and key intermediates at a quality and scale suitable for pre-clinical studies. The RNA Accelerator is supported by the NSW RNA Production and Research Network, which aims to make capabilities available state-wide to academic partners as well as industry.

The RNA Accelerator offers capabilities across the development and production pipeline for RNA-based therapeutics including: 
  • Plasmid DNA production, purification and characterisation 
  • mRNA production, purification and characterisation 
  • Synthetic RNA and DNA production, purification and characterisation (including siRNA, gRNA and oligoDNA) 
  • Lipid NP formulations, purification and analysis 

RNA Accelerator production scales range from small research projects up to the following approximate limits: 
  • pDNA up to 10 L scale (20 – 50 mg per batch) 
  • mRNA up to 10 L scale (>1 g purified mRNA) 
  • Synthetic RNA and DNA (sRNA, including siRNA and up to guide RNA ≈ 80-100 nt) up to 1 g sRNA 
  • Lipid NP formulations up to 20 mL 

Synthentic RNA Production

pDNA Production

mRNA Production

Lipid Nanoparticle Formulation diagram